A Network Pharmacology Study to Uncover the Multiple Molecular Mechanism of the Chinese Patent Medicine Toujiequwen Granules in the Treatment of Corona Virus Disease 2019 (COVID-19)

Abstract

Since the outbreak of the novel corona virus disease 2019 (COVID-19) at the end of 2019, specific antiviral drugs have been lacking. A Chinese patent medicine Toujiequwen granules has been promoted in the treatment of COVID-19. The present study was designed to reveal the molecular mechanism of Toujiequwen granules against COVID-19. A network pharmacological method was applied to screen the main active ingredients of Toujiequwen granules. Network analysis of 149 active ingredients and 330 drug targets showed the most active ingredient interacting with many drug targets is quercetin. Drug targets most affected by the active ingredients were PTGS2, PTGS1, and DPP4. Drug target disease enrichment analysis showed drug targets were significantly enriched in cardiovascular diseases and digestive tract diseases. An “active ingredient-target-disease” network showed that 57 active ingredients from Toujiequwen granules interacted with 15 key targets of COVID-19. There were 53 ingredients that could act on DPP4, suggesting that DPP4 may become a potential new key target for the treatment of COVID-19. GO analysis results showed that key targets were mainly enriched in the cellular response to lipopolysaccharide, cytokine activity and other functions. KEGG analysis showed they were mainly concentrated in viral protein interaction with cytokine and cytokine receptors and endocrine resistance pathway. The evidence suggests that Toujiequwen granules might play an effective role by improving the symptoms of underlying diseases in patients with COVID-19 and multi-target interventions against multiple signaling pathways related to the pathogenesis of COVID-19.

Keywords

Toujiequwen granules / COVID-19 / network pharmacology / target / molecular mechanism

References

[1] RioCD, MalaniPN. 2019 Novel Coronavirus-Important Information for Clinicians. JAMA, 2020, 323(11): 1039-1040

[2] WrappD, WangNS, CorbettKS, et al.. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 2020, 367(6483): 1260-1263

[3] ZumlaA, ChanJ, AzharE, et al.. Coronaviruses — drug discovery and therapeutic options. Nat Rev Drug Discov, 2016, 15(5): 327-347

[4] GaoY, QiuHB, ZhouS, et al.. Accumulated Clinical Experiences from Successful Treatment of 1377 Severe and Critically Ill COVID-19 Cases. Curr Med Sci, 2020, 40(4): 597-601

[5] FuX, LinL, TanX. Clinical study on 37 case of COVID-19 treated with integrated traditional Chinese and Western Medicine. Zhongyao Xinyao yu Linchuang Yaoli (Chinese), 2020, 31(5): 600-604

[6] FuX, LinL, TanX. Clinical Study on Treatment of Cases of COVID-19 with Toujie Quwen Granules. Zhongguo Shiyan Fangjixue Zazhi (Chinese), 2020, 26(12): 44-48

[7] SohnEJ, KimJM, KangSH, et al.. Restoring Effects of Natural Anti-Oxidant Quercetin on Cellular Senescent Human Dermal Fibroblasts. Am J Chinese Med, 2018, 46(4): 853-873

[8] ZhangD, FangJ, ChenJ, et al.. An in vitro study of antihuman cytomegalovirus effect of Forsythia suspensa and its main active ingredient quercetin. Zhongguo Zhongyao Zazhi (Chinese), 2010, 35(8): 1055-1059

[9] Zhang ZM, Guo SJ, Fu SJ, et al. Research Progress of Active Ingredients and Pharmacological Action of Honeysuckle. Animal Husbandry Feed Sci, 2014(1):22–24

[10] SunY, XiongYY, WuHZ, et al.. Active Ingredients and Mechanism of Action of Rhizoma Coptidis against Type 2 Diabetes Based on Network-Pharmacology and Bioinformatics. Curr Med Sci, 2020, 40(2): 257-264

[11] XiongWC, WuHZ, XiongYY, et al.. Network Pharmacology-based Research of Active Components of Albiziae Flos and Mechanisms of Its Antidepressant Effect. Curr Med Sci, 2020, 40(1): 123-129

[12] HopkinsA. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol, 2008, 4(11): 682-690

[13] LiuXK, WuJR, ZhangD, et al.. A Network Pharmacology Approach to Uncover the Multiple Mechanisms of Willd. on Colorectal Cancer. Evid Based Complement Alternat Med, 2018, 2018: 1-12

[14] LiuJ, PeiM, ZhengC, et al.. A Systems-Pharmacology Analysis of Herbal Medicines Used in Health Improvement Treatment: Predicting Potential New Drugs and Targets. Evid Based Complement Alternat Med, 2013, 2013(6): 938764

[15] ShannonP, MarkielA, OzierO, et al.. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res, 2003, 13(11): 2498-2504

[16] XuZ, ShiL, WangYJ, et al.. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med, 2020, 8(4): 420-422

[17] YuGC, WangLG, HanYY, et al.. clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters. Omics, 2012, 16(5): 284-287

[18] XuH. Research progress of prostaglandin receptors and related drugs. J China Pharm Univ, 2010, 41(5): 385-394

[19] McdougallC, MckayGA, FisherM. Drugs for diabetes: Part 5 DPP-4 inhibitors. Br J Cardiol, 2011, 18(3): 130-132

[20] KitanoH. Systems Biology: A Brief Overview. Science, 2002, 295(5560): 1662-1664

[21] WangZP, XuXJ. scRNA-seq Profiling of Human Testes Reveals the Presence of ACE2 Receptor, a Target for SARS-CoV-2 Infection, in Spermatogonia, Leydig and Sertoli Cells. Cell, 2020, 9(4): 920

[22] XiaoF, TangMW, ZhengXB, et al.. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology, 2020, 158(6): 1831-1833

[23] MaoL, JinHJ, WangMD, et al.. Neurologic Manifestations of Hospitalized Patients with Corona-virus Disease 2019 in Wuhan, China. JAMA Neurol, 2020, 77(6): 683-690

[24] ZhiP, YangXL, WangXG, et al.. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020, 579(7798): 270-273

[25] XuXT, ChenP, WangJF, et al.. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci, 2020, 63(3): 457-460

[26] LiuYX, YangY, ZhangC, et al.. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci, 2020, 63(3): 364-374